Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by toade1313 on Mar 21, 2024 4:12pm

63 Treated ?

Are we still at 63 patients treated that we were last November? Management owes us an update. Yes, ALL of us.
Comment by StevenBirch on Mar 21, 2024 4:37pm
That is the good thing about the PP, when it closes they will probably give an update.
Comment by Alamir1111 on Mar 21, 2024 4:46pm
Yes Steven I agree we should get uptades at every 2 to 3 months whenever pp is raised.
Comment by 2b7f6fab on Mar 21, 2024 5:14pm
smallish pp are probably better till we gain btd.  large institutional players looking at our trial performance to date and suspecting we could have similar response with gioblastoma and nsclc would lust to take a big bite of this apple.  I'm betting on it.
Comment by Alamir1111 on Mar 21, 2024 5:27pm
https://stockhouse.com/news/press-releases/2016/10/28/theralase-increases-gbm-brain-cancer-survival-by-925
Comment by Yajne on Mar 21, 2024 11:41pm
Thanks Alamir1111, although that NR was 7-1/2 years ago, it's a great reminder of the potential that TLT offers on other indications. Just need to get past this initial BTD hurdle for NMIBC, then hopefully  momentum into other indications
Comment by 2b7f6fab on Mar 22, 2024 1:27am
Nuts, I was such a great speller in fourth grade.  It's glioblastoma multiforme,...are lusting, not would lust....oh well. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250